Dysregulation of miR-335-5p in People with Obesity and its Predictive Value for Metabolic Syndrome

Abstract

The epidemic of obesity and metabolic syndrome has become the most serious global public health problem. The part played by microRNA (miRNA) in the onset and progression of obesity and metabolic syndrome has been increasingly focused upon. The goal of this study was to explore miR-335-5p as a potential predictive biomarker or therapeutic target for obesity and metabolic syndrome. The expression level of miR-335-5p was detected by qRT-PCR. The diagnostic value of miR-335-5p was evaluated by ROC curve. The association between serum miR-335-5p levels and various clinical parameters was assessed using the chi-square test. Logistic regression analysis was used to evaluate the risk factors of metabolic syndrome in obese population. The biological processes and molecular mechanisms are studied through GO and KEGG enrichment analysis. The ROC curve analysis revealed that miR-335-5p could serve as a predictive indicator for the development of obesity accompanied by metabolic syndrome. Logistic regression analysis revealed that BMI, TG, FBG, HOMA-IR, and miR-335-5p expression represent independent risk factors of metabolic syndrome occurrence. Chi-square test analysis revealed that patients with higher values of BMI, SBP, DBP, TG, FBG, and HOMA-IR exhibited a more significantly increased expression of miR-335-5p in their serum. In conclusion, miR-335-5p holds predictive and diagnostic value for obesity and metabolic syndrome and has potential to serve as a biomarker for these conditions.

Keywords

obesity -  metabolic syndrome - mir-335-5p - diagnosis

Publikationsverlauf

Eingereicht: 22. Dezember 2023

Angenommen nach Revision: 02. Februar 2024

Artikel online veröffentlicht:
06. März 2024

• References

• 1 Kristensen MS, Teoh WH, Rudolph SS. et al. A randomised cross-over comparison of the transverse and longitudinal techniques for ultrasound-guided identification of the cricothyroid membrane in morbidly obese subjects. Anaesthesia 2016; 71: 675-683
• 2 Afshin A, Forouzanfar MH, Reitsma MB. et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017; 377: 13-27
• 3 Golden A. Obesity's impact. Nurs Clin North Am 2021; 56: xiii-xiv
• 4 Kolotkin RL, Meter K, Williams GR. Quality of life and obesity. Obes Rev 2001; 2: 219-229
• 5 Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am 2014; 43: 1-23
• 6 Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world--a growing challenge. N Engl J Med 2007; 356: 213-215
• 7 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428
• 8 Hogg DR, Harries LW. Human genetic variation and its effect on miRNA biogenesis, activity and function. Biochem Soc Trans 2014; 42: 1184-1189
• 9 Assmann TS, Milagro FI, Martínez JA. Crosstalk between microRNAs, the putative target genes and the lncRNA network in metabolic diseases. Mol Med Rep 2019; 20: 3543-3554
• 10 Rottiers V, Näär AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012; 13: 239-250
• 11 Ma Y, Murgia N, Liu Y. et al. Neuronal miR-29a protects from obesity in adult mice. Mol Metab 2022; 61: 101507
• 12 Wang D, Fei Z, Luo S. et al. MiR-335-5p Inhibits β-amyloid (Aβ) accumulation to attenuate cognitive deficits through targeting c-jun-N-terminal kinase 3 in Alzheimer's disease. Curr Neurovasc Res 2020; 17: 93-101
• 13 Lu X, Li Y, Chen H. et al. miR-335-5P contributes to human osteoarthritis by targeting HBP1. Exp Ther Med 2021; 21: 109
• 14 Wang C, Jiang H. Long non-coding RNA PCAT19 regulates the malignant progression of bladder cancer through the miR-335-5p/IER2 axis. Crit Rev Eukaryot Gene Expr 2022; 32: 81-94
• 15 Fan XQ, Li H, Zhu HX. et al. [Effects of miR-335-5p targeting G6PD on proliferation and apoptosis of colon cancer cells]. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2021; 37: 402-406
• 16 Song G, Ma Y, Ma Y. et al. miR-335-5p Targets SDC1 to regulate the progression of breast cancer. Crit Rev Eukaryot Gene Expr 2022; 32: 21-31
• 17 Oger F, Gheeraert C, Mogilenko D. et al. Cell-specific dysregulation of microRNA expression in obese white adipose tissue. J Clin Endocrinol Metab 2014; 99: 2821-2833
• 18 Weng J, Ji L, Jia W. et al. Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev 2016; 32: 442-458
• 19 Wu J, Xu H, He X. et al. Six-year changes in the prevalence of obesity and obesity-related diseases in Northeastern China from 2007 to 2013. Sci Rep 2017; 7: 41518
• 20 Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003; 32: 805-822 viii
• 21 Kotsis V, Stabouli S, Papakatsika S. et al. Mechanisms of obesity-induced hypertension. Hypertens Res 2010; 33: 386-393
• 22 Zhang B, Xing L, Wang B. Dysregulation of circulating miR-24-3p in children with obesity and its predictive value for metabolic syndrome. Obes Facts 2021; 14: 456-462
• 23 Estrella Ibarra P, García-Solís P, Solís-Sáinz JC. et al. Expression of miRNA in obesity and insulin resistance: a review. Endokrynol Pol 2021; 72: 73-80
• 24 Castaño C, Kalko S, Novials A. et al. Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice. Proc Natl Acad Sci U S A 2018; 115: 12158-12163
• 25 Dandare A, Liaquat A, Rafiq M. et al. Circulating miR-548c-3p possesses good diagnostic potential for metabolic syndrome. Genes Dis 2023; 10: 683-686
• 26 Hess AL, Larsen LH, Udesen PB. et al. Levels of circulating miR-122 are associated with weight loss and metabolic syndrome. Obesity (Silver Spring) 2020; 28: 493-501
• 27 Guo J, Lin Y, Wei J. et al. Diagnostic value of serum MiR-587 in patients with metabolic syndrome. Clin Lab 2019; 65
• 28 Li G, Zhang L. miR-335-5p aggravates type 2 diabetes by inhibiting SLC2A4 expression. Biochem Biophys Res Commun 2021; 558: 71-78
• 29 Alberti KG, Eckel RH, Grundy SM. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645
• 30 Fulop T, Tessier D, Carpentier A. The metabolic syndrome. Pathol Biol (Paris) 2006; 54: 375-386
• 31 Bener A, Yousafzai MT, Darwish S. et al. Obesity index that better predict metabolic syndrome: body mass index, waist circumference, waist hip ratio, or waist height ratio. J Obes 2013; 269038
• 32 Solheim MH, Clermont AC, Winnay JN. et al. Iris malformation and anterior segment dysgenesis in mice and humans with a mutation in PI 3-kinase. Invest Ophthalmol Vis Sci 2017; 58: 3100-3106
• 33 Thon M, Hosoi T, Ozawa K. Possible integrative actions of leptin and insulin signaling in the hypothalamus targeting energy homeostasis. Front Endocrinol (Lausanne) 2016; 7: 138
• 34 Roy R, Yang J, Shimura T. et al. Escape from breast tumor dormancy: the convergence of obesity and menopause. Proc Natl Acad Sci U S A 2022; 119: e2204758119